medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2022, Number 3

<< Back Next >>

Rev Nefrol Dial Traspl 2022; 42 (3)

Update on the treatment of acute renal failure secondary to multiple myeloma, our experience in 27 cases treated with High Cut Off filters

Coscojuela OA, Berni WA, Dourdil SV, Iñigo GP, Álvarez LR

Language: Spanish
References: 27
Page: 199-205
PDF size: 197.30 Kb.


ABSTRACT

Introduction: Acute renal failure is a frequent complication of multiple myeloma that can affect 18 to 56% of patients and more than 10% will end up needing dialysis. Improved kidney function is also associated with longer survival, so we must eliminate the free light chains responsible for cast nephropathy as quickly as possible. Material and methods: A retrospective analysis of the 27 treatments that were performed with hemodialysis with High Cut Off filters to 24 patients (and 3 recurrences) was carried out in the period between July 2011 and May 2018. 288 sessions were performed in total with an average of 10.66 sessions/treatment. Results: At the end of treatment, 23 of the 27 cases (85.2%) recovered kidney function to allow living independently of dialysis (GFR › 15 mL/min), 4 patients needed to continue on dialysis. At 3 months, the number of patients who remained independent of dialysis was 20 of the 27 treated cases (74.1%), 3 patients died before 3 months (11%) due to complications related to myeloma, but without dialysis. Reviewing our data in May 2018, after almost 7 years of having started this type of treatment, we saw that 50% of patients lived without the need for dialysis. Conclusions: Given our experience, we believe that prolonged hemodialysis with High Cut Off filters is effective, safe and with a high rate of renal recovery. Albumin loss during hemodialysis was not a major problem.


REFERENCES

  1. Alexanian R, Barlogie B, Dixon D. Renal failure inmultiple myeloma. Pathogenesis and prognosticimplications. Arch Intern Med. 1990;150(8):1693-5.

  2. Bladé J, Fernández-Llama P, Bosch F, Montolíu J,Lens XM, Montoto S, et al. Renal failure in multiplemyeloma: presenting features and predictors ofoutcome in 94 patients from a single institution.Arch Intern Med. 1998;158(17):1889-93. doi: 10.1001/archinte.158.17.1889.

  3. Rayner HC, Haynes AP, Thompson JR, RussellN, Fletcher J. Perspectives in multiple myeloma:survival, prognostic factors and disease complicationsin a single centre between 1975 and 1988. Q J Med.1991;79(290):517-25.

  4. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, SudK, et al. Renal involvement in multiple myeloma:a 10-year study. Ren Fail. 2000;22(4):465-77. doi:10.1081/jdi-100100888.

  5. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV,Dispenzieri A, Fervenza FC, et al. Improvement ofcast nephropathy with plasma exchange depends onthe diagnosis and on reduction of serum free lightchains. Kidney Int. 2008;73(11):1282-8. doi: 10.1038/ki.2008.108.

  6. Hutchison CA, Basnayake K, Cook M, Bradwell AR,Cockwell P. Free light chain hemodialysis increasesrenal recovery rate and improves patient survivalin patients with cast nephropathy. Nephrol DialTransplant. 2008;1(Suppl 2):ii9a.

  7. Sanders PW. Pathogenesis and treatment of myelomakidney. J Lab Clin Med. 1994;124(4):484-8.

  8. Chanan-Khan AA, Kaufman JL, Mehta J, RichardsonPG, Miller KC, Lonial S, et al. Activity and safetyof bortezomib in multiple myeloma patients withadvanced renal failure: a multicenter retrospectivestudy. Blood. 2007;109(6):2604-6. doi: 10.1182/blood-2006-09-046409.

  9. Ludwig H, Drach J, Graf H, Lang A, Meran JG.Reversal of acute renal failure by bortezomib-basedchemotherapy in patients with multiple myeloma.Haematologica. 2007;92(10):1411-4. doi: 10.3324/haematol.11463.

  10. Kastritis E, Anagnostopoulos A, Roussou M, GikaD, Matsouka C, Barmparousi D, et al. Reversibilityof renal failure in newly diagnosed multiple myelomapatients treated with high dose dexamethasonecontainingregimens and the impact of novel agents.Haematologica. 2007;92(4):546-9. doi: 10.3324/haematol.10759.

  11. Clark WF, Stewart AK, Rock GA, Sternbach M,Sutton DM, Barrett BJ, et al.; Canadian ApheresisGroup. Plasma exchange when myeloma presents asacute renal failure: a randomized, controlled trial. AnnIntern Med. 2005;143(11):777-84. doi: 10.7326/0003-4819-143-11-200512060-00005.

  12. Ritz E. Plasma exchange for acute renal failure ofmyeloma. Logical, yet ineffective. J Am Soc Nephrol.2006;17:914-6.

  13. Clark WF, Garg AX. Plasma exchange for myeloma. kidney: cast(s) away? Kidney Int. 2008;73(11):1211-3.doi: 10.1038/ki.2008.117.

  14. Hutchison CA, Cockwell P, Reid S, Chandler K,Mead GP, Harrison J, et al. Efficient removal ofimmunoglobulin free light chains by hemodialysisfor multiple myeloma: in vitro and in vivo studies. JAm Soc Nephrol. 2007;18(3):886-95. doi: 10.1681/ASN.2006080821.

  15. Álvarez Lipe R, Martín Marín F, Abascal Ruiz JA,Berni A, Dourdil V, Palomera L. Tratamiento de laira secundaria a mieloma múltiple con filtro de highcut-off. Dial Traspl. 2013;34(1):36-40. doi: 10.1016/j.dialis.2012.06.001.

  16. Álvarez-Lara MA, Martín-Malo A, Aljama-GarcíaP. Nuevas alternativas en el tratamiento del riñón delmieloma. Nefrología (Madr.). 2013;33(4):443-7. doi:10.3265/Nefrologia.pre2013.Jun.12138

  17. Johnson WJ, Kyle RA, Pineda AA, O’Brien PC,Holley KE. Treatment of renal failure associated withmultiple myeloma. Plasmapheresis, hemodialysis, andchemotherapy. Arch Intern Med. 1990;150(4):863-9.

  18. Clark WF, Stewart AK, Rock GA, Sternbach M,Sutton DM, Barrett BJ, et al.; Canadian ApheresisGroup. Plasma exchange when myeloma presents asacute renal failure: a randomized, controlled trial. AnnIntern Med. 2005;143(11):777-84. doi: 10.7326/0003-4819-143-11-200512060-00005.

  19. Rousseau-Gagnon M, Agharazii M, De Serres SA,Desmeules S. Effectiveness of haemodiafiltration withheat sterilized high-flux polyphenylene HF dialyzer inreducing free light chains in patients with myelomacast nephropathy. PLoS One. 2015;10(10):e0140463.doi: 10.1371/journal.pone.0140463.

  20. Testa A, Dejoie T, Lecarrer D, Wratten M, SereniL, Renaux JL. Reduction of free immunoglobulinlight chains using adsorption properties ofhemodiafiltration with endogenous reinfusion. BloodPurif. 2010;30(1):34-6. doi: 10.1159/000316684.

  21. Pendón-Ruiz de Mier MV, Álvarez-Lara MA, Ojeda-López R, Martín-Malo A, Carracedo J, Caballero-Villarrasco J, et al. Eficacia de la hemodiafiltracióncon regeneración del ultrafiltrado en la reducción decadenas ligeras en mieloma múltiple con insuficienciarenal. Nefrología (Madr.). 2013;33(6): 788-96. doi:10.3265/Nefrologia.pre2013.Sep.12176.

  22. Fabbrini P, Sirtori S, Casiraghi E, Pieruzzi F, GenovesiS, Corti D, et al. Polymethylmethacrylate membraneand serum free light chain removal: enhancingadsorption properties. Blood Purif. 2013;35(Suppl2):52-8. doi: 10.1159/000350849.

  23. Santoro A, Grazia M, Mancini E. The doublepolymethylmethacrylate filter (DELETE system) inthe removal of light chains in chronic dialysis patientswith multiple myeloma. Blood Purif. 2013;35(Suppl2):5-13. doi: 10.1159/000350837.

  24. Hutchison CA, Heyne N, Airia P, Schindler R, ZicklerD, Cook M, et al. Immunoglobulin free light chainlevels and recovery from myeloma kidney on treatmentwith chemotherapy and high cut-off haemodialysis.Nephrol Dial Transplant. 2012;27(10):3823-8. doi:10.1093/ndt/gfr773.

  25. 25 Marn Pernat A, Medved B, Gubenšek J, Premru V,Knap B, Buturovic-Ponikvar J, et al. Citrate extendedhigh cut-off hemodiafiltration for renal recovery inpatients with multiple myeloma. Ther Apher Dial.2016;20(3):251-5. doi: 10.1111/1744-9987.12432.

  26. Cantín Lahoz V, Rojo Zulaica EP, Vecino Soler A,Marcén Letosa M, Aznar Buil B. El fracaso renal agudopor mieloma múltiple: cuidados de los pacientes en unaunidad de hemodiálisis. Enferm Nefrol. 2014;17(2):135-43. doi: 10.4321/S2254-28842014000200008.

  27. Martín-Reyes G, Toledo-Rojas R, Torres de Rueda A,Sola-Moyano E, Blanca-Martos L, Fuentes-Sánchez L,et al. Tratamiento con hemodiálisis del fracaso renalagudo en el mieloma múltiple con filtros de alto poro(high cut-off). Nefrología (Madr.). 2012;32(1):35-43.




2020     |     www.medigraphic.com